InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Edick Paul R, Chief Executive Officer. Director active across 2 companies, notably Xeris Pharmaceuticals INC. Cumulatively, 11 reports have been recorded. Breakdown: 5 buys · 0 sell. Total volume traded: €939k. History available since 11 November 2021. The latest transaction was disclosed on 12 May 2022 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations11 total
100,000 shares@ US$1.40380.010% mcap14.4% of flowCommon StockSEC:0001867096-22-000067:0
Ideal exit: 6 Feb 2023 (T+270)
600,000 shares0Common StockSEC:0001867096-22-000007:0
600,000 shares0Common StockSEC:0001867096-22-000007
20,000 shares@ US$2.28320.0031% mcap4.3% of flowCommon StockSEC:0001867096-21-000080:0
Ideal exit: 12 Aug 2022 (T+270)
20,000 shares@ US$2.28320.0031% mcap9.9% of flowCommon StockSEC:0001867096-21-000080
Ideal exit: 12 Aug 2022 (T+270)
200,000 shares@ US$2.07880.028% mcap38.5% of flowCommon StockSEC:0001867096-21-000076:0
Ideal exit: 8 Aug 2022 (T+270)
200,000 shares@ US$2.07880.028% mcap90.1% of flowCommon StockSEC:0001867096-21-000076
Ideal exit: 8 Aug 2022 (T+270)
197,231 sharesCommon StockSEC:0000899243-21-039335
197,231 sharesCommon StockSEC:0000899243-21-039254
197,231 sharesCommon StockSEC:0000899243-21-039254:0
197,231 sharesCommon StockSEC:0000899243-21-039335:0
11 of 11 declarations
About Edick Paul R
Paul R. Edick is the Chief Executive Officer of Xeris Pharmaceuticals Inc and Xeris Biopharma Holdings, Inc. He leads the strategic operations of these biopharmaceutical companies, focusing on innovation in medical treatments. His leadership is essential for advancing the research and development missions.
